Page last updated: 2024-09-04

tipifarnib and Lymphoma

tipifarnib has been researched along with Lymphoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allmer, C; Ansell, SM; Colgan, JP; Ding, H; Gupta, M; Habermann, TM; Hohl, R; Inwards, DJ; Johnston, PB; Kaufmann, SH; Kurtin, PJ; Link, BK; Loegering, D; Markovic, SN; Maurer, MJ; Micallef, IN; Nowakowski, GS; Peterson, K; Porrata, LF; Schneider, P; Tang, H; Thompson, CA; Weiner, G; Witzig, TE1

Trials

1 trial(s) available for tipifarnib and Lymphoma

ArticleYear
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
    Blood, 2011, Nov-03, Volume: 118, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult

2011